Press Release | Wed Dec 5, 2012 8:30am EST

Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breas

* Reuters is not responsible for the content in this press release.